Hypoglycaemia when adding sulphonylurea to metformin: a systematic review and network meta-analysis.

ABSTRACT:

Aims

The risk of hypoglycaemia may differ among sulphonylureas (SUs), but evidence from head-to-head comparisons is sparse. Performing a network meta-analysis to use indirect evidence from randomized controlled trials (RCTs), we compared the relative risk of hypoglycaemia with newer generation SUs when added to metformin.

Methods

A systematic review identified RCTs lasting 12-52 weeks and evaluating SUs added to inadequate metformin monotherapy (≥1000 mg/day) in type 2 diabetes. Adding RCTs investigating the active comparators from the identified SU trials, we established a coherent network. Hypoglycaemia of any severity was the primary end point.

Results

Thirteen trials of SUs and 14 of oral non-SU antihyperglycaemic agents (16 260 patients) were included. All report

SUBMITTER: Andersen SE 

PROVIDER: S-EPMC5061791 | biostudies-literature | 2016 Nov

REPOSITORIES: biostudies-literature